These quantitative findings justify considering liposome-in-hydrogel formats when the target is oral or mucosal delivery of peptides (e.g., insulin) or when both systemic bioavailability and sustained local action are required in metabolic disease interventions. The gene discussed is INS; the disease is metabolic disease.